There are plenty of reasons why many investors enjoy holding shares in Johnson & Johnson (NYSE: JNJ), one of the world's largest healthcare businesses. With the company's impressive track record of dividend payments and its pipeline's massive throughput of new medicines, it's clear that this stock will be around for the foreseeable future. Johnson & Johnson's product mix makes it worth buying in times like now when inflation is higher than average.
Johnson & Johnson is facing issues that are causing investors to look elsewhere (more on those below). Let's look into why opportunistic investors should seriously consider buying shares of Johnson & Johnson as they sink. On Jan. 24, Johnson & Johnson released its fourth-quarter and full-year 2022 financial results.
In fact, two stocks that outperformed the S&P 500 last year are now down more than 6% since the start of the year: Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV).. Motley Fool contributors Adria Cimino and Keith Speights talk about why these two stocks actually make great buys right now. Adria Cimino (Johnson & Johnson): J&J may have disappointed investors when it reported fourth-quarter earnings on Jan. 24.